OncoSec Medical, through the continued clinical development
of its proprietary ImmunoPulse™ intratumoral cancer immunotherapy, is preparing
to revolutionize the cancer treatment market. The company’s innovative
therapeutic delivery system is designed to enhance local delivery and reception
of DNA-based therapeutics through the use of electroporation, or electrical
stimulation, meant to increase the permeability of the cell membrane. By
supplying a sequence of short-duration electrical pulses to a tumor,
ImmunoPulse has been shown effective in dramatically improving the uptake of
DNA-based agents, thereby increasing the effectiveness of treatment options for
various types of cancers by educating immune cells to recognize the disease.
To date, the company has primarily studied the benefits of
its ImmunoPulse technology in combination with its DNA-based IL-12, a naturally
occurring protein with immune-stimulating functions. OncoSec’s clinical
pipeline currently includes phase II clinical studies of IL-12 for the
treatment of metastatic melanoma, head and neck cancer and triple negative
breast cancer. In early tests, the company has recorded promising results. In
its multi-center phase II trial of IL-12 as a treatment for metastatic
melanoma, half of all patients showed complete regression in at least one
untreated lesion, demonstrating the immune-stimulating functions of the
therapeutic. For OncoSec and its ImmunoPulse delivery system, these results
could be just the beginning.
“While we work to advance our clinical studies, we are also
continuing to explore the broader applications of our ImmunoPulse technology,”
Punit Dhillon, president and chief executive officer of OncoSec, stated in a
news release. “While our engineers work to develop advanced devices capable of
accessing difficult-to-reach tumors, the discovery research team is
investigating new DNA constructs and targets focused on defeating cancer’s
ability to evade the immune system, allowing the patient’s immune system to
recognize and attack the tumor.”
For prospective shareholders, the vast market potential of
OncoSec’s therapeutic delivery system makes the company an intriguing
investment opportunity moving forward. As of April 30, the company reported
$25.4 million in cash and cash equivalents, which it expects will adequately
fund operations for the next year. Additionally, the company’s uplisting to the
NASDAQ Capital Market, which it completed in May, should provide a platform for
increased visibility when the need for additional funding arises. With
financial flexibility in place, OncoSec is in a strong position to make
continued progress toward the eventual commercialization of its groundbreaking
therapeutic pipeline in the coming months.
For more information, visit www.oncosec.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
